drugset / Trial / NCT04661527
Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19
Phase 2
Unknown
60 enrolled
Clinica Universidad de Navarra, Universidad de Navarra
Hospital Universitario Infanta Leonor · collabSanofi · collab
NaSingle-groupOpen-labelTreatment
Summary
Phase II, one-arm, open label, multicentric study, to evaluate treatment of severe COVID-19 with sarilumab prior to entry into the intensive care unit (ICU).
Timeline
- Start
- 2020-04-22
- Primary completion
- 2020-12-30
- Completion
- 2020-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sarilumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Sarilumab | Monoclonal antibody | 400 mg | Intravenous |
Indications
No indication recorded.